QTEX (QTEX) Stock Price & Analysis
QTEX (QTEX) rose 13.48% to USD 1.6 as of June 10, 2026 at 01:07 UTC, according to Nexqual real-time market data.
QTEX last closed at USD 1.41; the session ranged USD 1.45–1.84 on volume of 42,461,185 shares. Market capitalization is $72.41M, with a 52-week range of USD 0.28–3.85 (NCM). Source: Nexqual, June 10, 2026 at 01:07 UTC.
Key Statistics (as of June 10, 2026 at 01:07 UTC)
| Price | USD 1.6 |
|---|---|
| Change | ▲ 13.48% (up) |
| Previous Close | USD 1.41 |
| Open | USD 1.56 |
| Day Range | USD 1.45 – 1.84 |
| 52-Week Range | USD 0.28 – 3.85 |
| Volume | 42,461,185 shares |
| Market Cap | $72.41M |
| Exchange | NCM |
Technical Analysis (QTEX)
Nexqual's technical model rates QTEX "STRONG BUY" based on 5 bullish and 0 bearish signals across 124 daily candles, as of June 10, 2026 at 01:07 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 54.08 (neutral) |
| vs SMA50 | Above (USD 0.83) |
| MACD | 0.34 (positive) |
Analyst Ratings (QTEX)
Wall Street analysts rate QTEX "None" based on 1 analysts, with a mean price target of USD 5 (range USD 5–5), per Nexqual as of June 10, 2026 at 01:07 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 5 |
| High Target | USD 5 |
| Low Target | USD 5 |
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (QTEX)
Source: Nexqual, June 10, 2026 at 01:07 UTC.
Financials & Fundamentals (QTEX)
| Total Revenue | $289,000 |
|---|---|
| Gross Margin | +0.69% |
| Operating Margin | -4713.84% |
| Profit Margin | +0.00% |
| ROE | -397.89% |
| Debt / Equity | 20.66 |
| Current Ratio | 1.56 |
| Total Cash | $3.16M |
| Total Debt | $480,000 |
| Free Cash Flow | $-5.67M |
Source: Nexqual, June 10, 2026 at 01:07 UTC.
Financial Health Score (QTEX)
Nexqual rates QTEX's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 01:07 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $3M cash, no debt |
| Cash Flow | Weak — FCF negative: -$6M, burning cash |
| Efficiency | Critical — ROE -398%, ROA -127.0% |
Ownership (QTEX)
| Insider Ownership | +9.17% |
|---|---|
| Institutional Ownership | +13.49% |
| Shares Outstanding | 45.25M |
| Float | 33.22M |
| Short % of Float | +19.79% |
Source: Nexqual, June 10, 2026 at 01:07 UTC.
Leadership (QTEX)
QTEX is led by Dagi Shahar Ben-Noon (age 49), Co-Founder, CEO & Director, per Nexqual as of June 10, 2026 at 01:07 UTC.
| Co-Founder, CEO & Director | Dagi Shahar Ben-Noon (age 49) |
|---|---|
| Chief Financial Officer | Yafit Tehila (age 44) |
| COO and VP of Research & Development | Avi Shabtai (age 51) |
| Chief Technology Officer | Daniella Yeheskely-Hayon (age 49) |
| Director of Marketing | Adi Shmueli |
Major Backers & Investors (QTEX)
Notable institutional backers of QTEX include Armistice Capital, LLC, Yorkville Advisors Global, LP, Kestra Advisory Services, LLC, according to Nexqual as of June 10, 2026 at 01:07 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Armistice Capital, LLC | 9.5% |
| Yorkville Advisors Global, LP | 4.54% |
| Kestra Advisory Services, LLC | 0.18% |
| Susquehanna International Group, LLP | 0.14% |
| Xtx Topco Ltd | 0.12% |
Source: Nexqual, June 10, 2026 at 01:07 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ENSC | Ensysce Biosciences, Inc. | USD 0.25 | ▲ 0% |
| BFRI | Biofrontera Inc. | USD 0.88 | ▼ 5.88% |
| ISPC | iSpecimen Inc. | USD 2.92 | ▼ 3.31% |
| PTPI | Petros Pharmaceuticals, Inc. | USD 0.01 | ▲ 8.33% |
| KTTA | Pasithea Therapeutics Corp. | USD 0.58 | ▼ 0.85% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 01:07 UTC. This page is informational and not investment advice.